EMERGENCY:After a recent viral illness: weakness in both legs spreading upward over hours or days (possible Guillain-Barré syndrome); difficulty climbing stairs, getting up from a chair, or holding things with tingling/numbness; difficulty swallowing, slurred speech, or facial weakness on both sides; shortness of breath (especially lying flat) or shallow rapid breathing; sudden severe back pain with leg weakness and bladder symptoms; an irregular pulse, fainting, or unexplained sweating with new weakness. GBS can progress from a tingle in the toes to needing a ventilator within 24–72 hours — do not wait. —call040-46324365immediately — 24 hours, 7 days— 24/7
Post-Viral Polyneuropathy — Diagnosis & Treatment in Hyderabad at KIMS
Post-viral polyneuropathy is weakness, numbness, or pain in many nerves at once, appearing after a viral illness. The most well-known form is Guillain-Barré syndrome (GBS), but post-viral nerve trouble can take several shapes — from a mild, slow tingling in the hands and feet after dengue, to a rapid, severe paralysis after a simple stomach upset that needs intensive care. Most patients recover, often completely, but the recovery is faster and more complete when treatment is started early.
Post-viral polyneuropathy is damage to the peripheral nerves following a viral or bacterial infection. The most important and most severe form is Guillain-Barré syndrome (GBS) — an acute, potentially life-threatening immune-mediated polyneuropathy triggered by molecular mimicry between microbial antigens and peripheral nerve gangliosides or myelin. GBS is the most common cause of acute flaccid paralysis in India and globally. The most common trigger is Campylobacter jejuni gastroenteritis (10–14 days before neurological onset). Other triggers: dengue, COVID-19, Zika, influenza, CMV, EBV. CSF: albumino-cytological dissociation (elevated protein with normal or near-normal cell count) — the pathognomonic CSF finding. Nerve conduction studies: AIDP (demyelinating, most common globally) shows slow conduction velocity; AMSAN (more common in India) shows reduced amplitude with preserved or near-normal velocity. Respiratory failure: the most life-threatening complication; FVC and NIF monitored every 4 hours in progressive GBS. Treatment: IVIG (0.4 g/kg/day for 5 days) or plasmapheresis (5 sessions), equally effective, not combined. Post-dengue and post-COVID polyneuropathies are milder but documented variants.
- GBS mechanism — Campylobacter and molecular mimicry
- Campylobacter jejuni is the most common identified trigger (20–30% of GBS). Its lipopolysaccharides resemble peripheral nerve gangliosides (GM1, GD1a, GD1b); the immune response to the bacterium cross-reacts with motor and sensory nerves 1–4 weeks after the diarrhoea has resolved. Other triggers: dengue, COVID-19 (2–6 weeks post), Zika, influenza, CMV, EBV, Mycoplasma pneumoniae.
- Albumino-cytological dissociation — the CSF hallmark
- Elevated CSF protein (0.5–10 g/L) with a normal or near-normal cell count (usually <10 white cells/mm³). Reflects blood-nerve barrier breakdown without CSF cellular inflammation. A normal LP in the first 1–2 weeks does NOT exclude GBS — repeat at 2 weeks if clinical suspicion remains high.
- AIDP and the axonal variants in India
- AIDP (demyelinating): prolonged distal latencies, slowed velocities, F-wave abnormalities. AMAN and AMSAN (axonal): reduced CMAP/SNAP amplitudes with preserved velocities, often more rapid onset, more severe weakness, and slower or less complete recovery; AIDP generally has the better prognosis. Both the demyelinating and axonal forms occur in India, and their relative frequency varies among studies and patient populations — some Indian studies show AIDP predominating, while others report a higher proportion of axonal variants, particularly with Campylobacter jejuni-associated GBS. No single India-wide frequency figure applies across all settings.
- Respiratory monitoring — the most urgent management principle
- FVC and NIF every 4 hours in all progressive GBS patients. Intubation thresholds: FVC <15–20 mL/kg OR NIF less negative than −30 cmH₂O OR rapidly declining FVC OR inability to count to 20 in a single breath. Also: dysphagia with aspiration risk, autonomic instability, bilateral facial palsy. Elective intubation is always preferable to emergency intubation.
- IVIG vs plasmapheresis — equally effective, do not combine
- IVIG 0.4 g/kg/day for 5 days OR plasmapheresis 5 sessions over 10 days. Both have Level 1 evidence; equally effective in randomised trials. The combination is NOT superior. IVIG preferred at KIMS for most patients (simpler administration). Plasmapheresis preferred when IVIG is unavailable or in IgA deficiency.
- Post-dengue polyneuropathy — India-specific entity
- A less severe but documented peripheral nerve complication of dengue fever in South India. Can present as GBS (most severe, 1–4 weeks after acute dengue), mononeuropathy (facial palsy, cranial nerve palsies), or a milder painful polyneuropathy with burning feet and distal weakness. Most cases resolve with IVIG or supportive care.
- Long-COVID peripheral neuropathy — the post-pandemic entity
- Distal small-fibre neuropathy producing burning feet, hyperalgesia, allodynia, and autonomic symptoms (orthostatic tachycardia, sweating abnormalities). Skin biopsy shows reduced intraepidermal nerve fibre density; standard NCS may be normal. Management: gabapentin, duloxetine, or pregabalin; structured exercise rehabilitation; autonomic management for POTS. Most improve over 6–18 months.
| Fact | Details |
|---|---|
| GBS triggers in India | Campylobacter jejuni (most common, 1–4 weeks post-GI illness) · Dengue · COVID-19 (2–6 weeks post) · Influenza · CMV · EBV · Zika |
| CSF hallmark | Albumino-cytological dissociation: elevated protein (0.5–10 g/L) + normal or near-normal cell count (<10 cells/mm³) · May be normal in first 1–2 weeks |
| NCS variants | AIDP: slow conduction velocity (demyelinating) · AMAN/AMSAN: reduced amplitude, normal velocity (axonal) · Both forms occur in India; relative frequency varies among studies and populations · Axonal variants generally carry the worse prognosis |
| Respiratory monitoring | FVC and NIF every 4 hours in progressive GBS · Intubation threshold: FVC <15–20 mL/kg or NIF <−30 cmH₂O · Elective intubation preferable to emergency |
| Treatment | IVIG 0.4 g/kg/day × 5 days OR plasmapheresis 5 sessions · Do NOT combine · IVIG preferred at KIMS for most patients · 24×7 plasmapheresis available |
| Post-viral variants in India | Post-dengue neuropathy (seasonal) · Post-COVID neuropathy (small-fibre, burning feet) · All require NCS for characterisation |
| Contact | 040-46324365 (emergency: spreading leg weakness, breathing difficulty, inability to swallow) · 040-44885000 (outpatient: post-viral tingling or weakness) |
About This Condition
Post-Viral Polyneuropathy at a Glance
What is it?
Damage or inflammation of many peripheral nerves at the same time, triggered by a recent viral infection.
Common forms
Guillain-Barré syndrome (GBS), small-fibre neuropathy, post-COVID neuropathy, post-dengue neuropathy, post-chikungunya neuropathy, post-Zika.
Indian context
Triggered by dengue, chikungunya, hepatitis A and E, viral hepatitis, COVID-19, and occasionally vaccinations. Often follows a stomach upset (Campylobacter).
Onset after the trigger
1–4 weeks for GBS; can be longer for slower forms.
Hallmark symptom
Weakness or numbness starting in the feet/hands and moving inward; reduced or absent reflexes.
Key test
Nerve conduction study with EMG; spinal fluid examination; targeted blood tests.
Treatment
IVIG or plasmapheresis for severe cases; supportive care; immunotherapy for autoimmune small-fibre neuropathy.
Outlook
70–85% of GBS patients walk again within 6 months; most other post-viral neuropathies recover well with time and supportive care.
Nerve Weakness After a Viral Fever — From Mild Tingling to GBS Emergency
Post-viral polyneuropathy is weakness, numbness, or pain in many nerves at once, appearing after a viral illness. The most well-known form is Guillain-Barré syndrome (GBS), but post-viral nerve trouble can take several shapes — from a mild, slow tingling in the hands and feet after dengue, to a rapid, severe paralysis after a simple stomach upset that needs intensive care. Most patients recover, often completely, but the recovery is faster and more complete when treatment is started early.
KIMS Neuroscience in Secunderabad runs a 24×7 service for acute post-viral neuropathy with same-day nerve conduction, neuro-ICU, IVIG, and plasmapheresis on site — and an outpatient programme for the slower, post-viral neuropathies seen after dengue, COVID-19, chikungunya, and other infections common in India.
Book a Post-Viral Nerve Assessment
Speak directly with the KIMS neurology and neuro-ICU teams — 24×7 cover, same-day nerve conduction studies, standardised IVIG protocol for paediatric and adult patients, on-site plasmapheresis 24×7, bedside breathing assessment in GBS, and a multidisciplinary rehabilitation team (physio, OT, speech, pain). Outpatient peripheral nerve and neuro-rehabilitation clinics run Monday to Saturday. Bring: hospital records of the trigger illness, current and previous medications, any previous nerve studies, blood reports, and a description of when weakness or symptoms began.
040-44885000Neuro Emergency: 040-46324365 (24×7)How a Viral Infection Damages the Nerves — and the Four Most Common Patterns
After a viral or bacterial infection, the immune system sometimes attacks the body's own nerves by mistake — targeting myelin, axon, or small-fibre endings. Different infections drive different patterns, producing four recognisable post-viral nerve syndromes: GBS, AMAN, small-fibre neuropathy, and CIDP.
How a viral infection damages the nerves
Peripheral nerves carry signals between the brain and the rest of the body — strength, sensation, balance, and the automatic control of heart, gut, sweat, and bladder. After a viral or bacterial infection, the immune system, having been switched on, sometimes attacks the body's own nerves by mistake. The attack can target the nerve's insulating layer (myelin) — slowing or blocking signals; the nerve fibre itself (axon) — interrupting them; or the tiny endings in the skin (small fibres) — causing burning and autonomic symptoms.
Different infections, different patterns
Different infections tend to cause different patterns. Campylobacter food poisoning often triggers an aggressive axonal attack. Dengue and COVID-19 frequently cause small-fibre injury. Hepatitis E is increasingly recognised as a trigger of severe GBS in India. Knowing the trigger helps predict the pattern and the likely recovery.
Guillain-Barré syndrome (GBS)
Fast, severe, symmetrical weakness with loss of reflexes; the form that most often needs ICU care.
Acute motor axonal neuropathy (AMAN)
A 'pure motor' form of GBS often seen after Campylobacter; common in India.
Small-fibre neuropathy
Burning, prickling, tingling in the feet and hands without much weakness, often with autonomic symptoms; common after dengue and COVID-19.
Chronic inflammatory demyelinating polyneuropathy (CIDP)
A slower, longer-lasting cousin of GBS that develops over months and responds to ongoing immunotherapy.
Post-Viral Polyneuropathy — Three Typical Pictures
Post-viral neuropathy presents in three recognisable clinical pictures: classical GBS with ascending weakness and loss of reflexes; post-dengue or post-COVID small-fibre neuropathy with burning pain and autonomic symptoms; and post-viral mononeuropathies/plexopathies such as Bell's palsy and neuralgic amyotrophy.
Guillain-Barré syndrome (GBS) — the classic story
Tingling and numbness in the toes, then the fingers. Weakness in the legs starting a few hours later — difficulty climbing stairs, then walking, then standing. Weakness spreads upward over hours to a few days — to the trunk, arms, face, and breathing muscles in severe cases. Loss of reflexes — the doctor's hammer tap produces no movement at the knees and ankles. Back and leg pain in 30–50%. Autonomic symptoms: irregular heart rate, swings in blood pressure, retention of urine.
Maximum weakness is reached within 2 weeks in most patients; recovery follows over weeks to months.
Post-dengue / post-COVID small-fibre neuropathy
Burning, electric, or 'pins and needles' pain in the feet and hands, sometimes the face. Worse at night, sometimes triggered by warmth or even bedsheets touching the skin. Often little or no muscle weakness. Autonomic symptoms — dizziness on standing, irregular sweating, palpitations, gut sluggishness.
Develops slowly over weeks to months after the viral illness.
Post-viral mononeuropathies and plexopathies
Weakness or numbness in the territory of one nerve — for example, sudden facial palsy (Bell's palsy) after a viral illness, or a painful arm with weakness after a chest infection (neuralgic amyotrophy).
Often resolves with time and supportive care.
Common Triggers in India
Different infections cause different post-viral nerve patterns. Knowing the trigger helps predict the pattern of nerve injury and shape treatment — from Campylobacter-driven severe AMAN to monsoon-peak dengue/chikungunya and the emerging post-COVID and hepatitis E presentations.
Campylobacter food poisoning
Severe AMAN form of GBS.
The most common identified trigger worldwide.
Dengue
GBS, small-fibre neuropathy, mononeuritis.
Seasonal — monsoon peak in Telangana/AP.
Chikungunya
GBS, small-fibre, peripheral nerve pain.
Often together with prolonged joint pain.
Hepatitis E
Severe GBS.
Increasingly recognised in Indian patients.
COVID-19
GBS, small-fibre, autonomic neuropathy.
Continues to be seen — both during and after infection.
Zika virus
GBS.
Rare in India but reported.
Cytomegalovirus, EBV
GBS, CIDP.
Usually in young adults.
Influenza
GBS — uncommonly.
Risk lower than from the flu itself.
Vaccinations
Very rare GBS.
Risk far lower than from natural infection.
Diagnosis at KIMS
How We Diagnose Post-Viral Polyneuropathy at KIMS
Post-viral polyneuropathy is diagnosed at KIMS through a structured seven-stage workflow that starts with a careful history and timeline, proceeds to a focused neurological and respiratory examination, then to same-day nerve conduction study and EMG (the single most important confirmatory test), lumbar puncture for albuminocytologic dissociation when GBS is suspected, blood tests for triggers and antibodies, MRI of the spine to exclude mimics, and skin biopsy for small-fibre neuropathy when nerve conduction studies are normal :
Detailed history and timeline
Exact pattern of weakness or sensory symptoms, how fast they spread, and how they relate in time to the viral trigger. Food history (suggests Campylobacter), travel, recent vaccinations, and medications.
Neurological examination
Pattern of weakness, reflex testing, sensory examination, cranial nerve testing, and autonomic checks (blood pressure lying and standing, heart-rate variability). Respiratory examination — including bedside breathing measurements when GBS is suspected.
Nerve conduction study and EMG
The single most important confirmatory test. Same-day reporting at KIMS. Tells us which nerves are involved, whether the damage is in the insulation (myelin) or the wire (axon), and how severe it is. May need to be repeated if done very early — the first few days of GBS can show normal nerve studies.
Lumbar puncture (CSF analysis)
The classic finding in GBS is 'albuminocytologic dissociation' — a high protein with normal cell counts. Useful when the picture is uncertain. Also helps exclude other causes such as infection or cancer.
Blood tests for triggers and antibodies
Tests for dengue, chikungunya, COVID-19, hepatitis viruses, Campylobacter serology. Antibodies against gangliosides (e.g. anti-GM1) when specific variants are suspected. Thyroid, vitamin B12, fasting sugar — to rule out other causes of neuropathy.
Imaging
MRI of the spine and spinal cord — to rule out compression, transverse myelitis, and other mimics. MR neurography in selected cases for complex neuropathies.
Skin biopsy for small-fibre neuropathy
A small punch biopsy of skin (usually from the leg) can confirm small-fibre damage when nerve conduction studies are normal. Particularly useful for the burning, painful, post-dengue and post-COVID forms.
Treatment
Treatment — Early Action Makes the Biggest Difference
For GBS — first-line treatment
IVIG (Intravenous Immunoglobulin) — 0.4 g/kg per day for 5 days. Effective, well-tolerated, and convenient. Plasmapheresis (plasma exchange) — usually 5 sessions on alternate days. Equally effective; chosen based on availability and patient factors. Both IVIG and plasmapheresis must be started within the first 2 weeks of weakness for best results. KIMS has both available 24×7, including on weekends and holidays.
For severe GBS — neuro-ICU care
Constant monitoring of breathing — bedside lung-function tests several times a day. Mechanical ventilation when breathing muscles fail — about 20–30% of GBS patients need this. Treatment of autonomic instability — blood pressure swings, heart-rate changes. Prevention of complications — pressure sores, deep-vein thrombosis, chest infection, malnutrition. Pain control — back pain is often severe and needs proper treatment.
For post-viral small-fibre and painful neuropathies
Anti-neuropathic medicines — pregabalin, gabapentin, duloxetine, amitriptyline. Selected patients with autoimmune small-fibre neuropathy may benefit from steroids or IVIG. Lifestyle measures — sleep, gentle exercise, treating any vitamin deficiency, stopping nerve-toxic medicines. Patience — these neuropathies improve slowly over months to a year.
For CIDP (the chronic form)
Long-term immunotherapy — usually IVIG infusions every 3–6 weeks, or steroids, or other immunomodulators. Regular review to adjust treatment based on response. Most CIDP patients live full lives with appropriate ongoing care.
Recovery — What to Expect
Recovery from post-viral polyneuropathy follows a predictable arc — from the acute and plateau phases in the first weeks, through the early recovery period at 2–6 months when most rapid functional gains occur, into late recovery over 6–24 months and a long-term trajectory in which 70–85% of GBS patients walk unaided by 6–12 months :
Week 1–2 (acute phase)
Symptoms reach their worst. Patient may be in ICU. Constant monitoring; treatment given.
Week 2–6 (plateau phase)
Stabilisation. Out of ICU. Physiotherapy and occupational therapy begin in earnest. Patients often start to feel their fingers and toes again — encouraging but slow.
Month 2–6 (early recovery)
Most rapid functional gains. Walking returns. Speech and swallowing recover. Fatigue is universal — pacing is essential.
Month 6–24 (late recovery)
Continued slow improvement. Fine motor skills, balance, and stamina improve. Some patients are left with mild residual weakness, foot drop, or numbness — usually manageable with physiotherapy and orthotics.
Long-term
About 70–85% of GBS patients walk without aid by 6–12 months. Around 10–15% have moderate residual disability. Severe residual disability is uncommon (under 5%) with timely treatment. Small-fibre neuropathies often take longer to improve and may need ongoing symptomatic care.
Factors That Predict Slower Recovery
Certain features at presentation predict a slower or less complete recovery. Even with these adverse factors, most patients improve substantially with structured care.
Age over 60 years
Older patients tend to have slower and less complete recovery.
Rapid onset to peak weakness (less than 7 days)
Faster progression to maximum weakness signals a more severe course and slower recovery.
Need for ventilation
Mechanical ventilation indicates respiratory muscle involvement and tends to predict longer recovery.
Severe axonal form on nerve conduction studies
Axonal damage takes longer to recover than demyelinating damage.
Diabetes, B12 deficiency, or other contributing nerve problems
Co-existing nerve disease compounds the post-viral injury and slows recovery. Even with adverse factors, most patients improve substantially with structured care.
Rehabilitation After Post-Viral Polyneuropathy
Long-term recovery depends not only on the immunotherapy but also on structured rehabilitation across physiotherapy, occupational therapy, speech and swallow therapy, and pain/fatigue management.
Physiotherapy
Started from day one — gentle passive movements when the patient is paralysed, then active exercises as strength returns. Targeted strengthening, balance training, gait re-education. Foot drop splints, walking aids, and orthotics as needed.
Occupational therapy
Re-learning daily activities — eating, dressing, bathing, writing, using a phone. Hand therapy for fine motor recovery. Workplace re-integration planning.
Speech and swallow therapy
For patients with bulbar (swallow and speech) involvement. Safe-swallow assessments before resuming oral feeding.
Pain and fatigue management
Pain after GBS can persist for months — addressed with medication and physical therapy. Fatigue is universal in the first year — managed with pacing, gradual activity, and treatment of sleep and mood.
KIMS — Service Highlights for Post-Viral Neuropathy
24×7 neurology and neuro-ICU cover
Yes.
Same-day nerve conduction study
100% of admitted patients.
IVIG protocol
Standardised, paediatric and adult.
Plasmapheresis on site
24×7.
Bedside breathing assessment in GBS
Several times daily.
GBS — patients walking unaided at 6 months
70–85%.
GBS — mortality with timely treatment
Under 5%.
Multidisciplinary rehabilitation team
Physio · OT · speech · pain.
Emergency line
040-46324365 (24×7).
Related Conditions
Post-viral polyneuropathy belongs to the family of neuro-infection complications evaluated and managed at KIMS Neuroscience. Explore related conditions
FAQs
Frequently Asked Questions
A tingle in the toes after a stomach upset. Burning feet weeks after dengue. A facial droop after a viral fever. Post-viral polyneuropathy is common, treatable, and time-sensitive — early IVIG or plasmapheresis transforms recovery.
At KIMS Neuroscience, Secunderabad, Hyderabad, post-viral polyneuropathy is managed under 24×7 neurology and neuro-ICU cover with same-day nerve conduction studies in 100% of admitted patients, a standardised IVIG protocol for paediatric and adult patients, on-site plasmapheresis 24×7, bedside breathing assessment several times daily in GBS, 70–85% of GBS patients walking unaided at 6 months, under 5% mortality with timely treatment, and a multidisciplinary rehabilitation team (physio, OT, speech, pain). Open emergency line: 040-46324365 (24×7). Outpatient peripheral nerve and neuro-rehabilitation clinics run Monday to Saturday. Appointments: 040-44885000. Email: neuroscience@kimshospitals.com. Bring: hospital records of the trigger illness, current and previous medications, any previous nerve studies, blood reports, and a description of when weakness or symptoms began.
International enquiries: info@kimsneurosciences.com